Navigation Links
CompanDX Ltd. and Clinical Reference Laboratory, Inc. Sign Multi-Year Deal in Support of Collaborative Gene Signature and Companion Diagnostic Development
Date:2/19/2011

LENEXA, Kan., Feb. 19, 2011 /PRNewswire/ -- CompanDX Ltd., bioinformatics partner for the life sciences industry, and Clinical Reference Laboratory, Inc. (CRL), provider of laboratory testing services in molecular diagnostics and clinical trials, today announced they entered into a multi-year agreement to collaborate in the development and support of biomarker panels and companion diagnostic development for pharmaceutical, biotech and academic clients worldwide. Under the terms of the agreement, CompanDX will continue its trailblazing bioinformatics work on its "Distiller" platform, which includes the development of the first "Time to Event" breast cancer signature supported by CRL's CLIA-certified laboratory services.

The agreement today paves the way for CRL and CompanDX to deliver "discovery to validated test" services to their respective clients.  "CRL has a strong, long-standing reputation for providing state-of-the-art CLIA-certified testing services. In forging this relationship it allows us to reach both upstream and downstream to significantly broadening our reach into the growing market of Molecular Diagnostics, Stratified Clinical Trails and Personalized Medicine," said AD Sutton, CEO, CompanDX.

"Clients are looking for our help to support their clinical development programmes either by reducing the complexity of genomic or proteomic data or by proving innovative MDx tests that will allow them to stratify clinical trials.  CRL brings a level of expertise in the design and delivery of MDx tests that ideally compliments our innovative approach."

CRL's Executive Director of Molecular Diagnostics, Dr. Heather Fehling agrees, "CRL and CompanDX created a powerful team to help meet client's challenges in identifying meaningful biomarker panels and developing novel MDx testing for those panels.  CRL is excited to link its years of CLIA-certified laboratory experience with CompanDX's cutting edge bioinformatics tools to create a unique team offering quality molecular services."

CompanDX's bioinformatics technology will be exhibited at CRL's Booth #630 at the Molecular Medicine Tri-Conference in San Francisco from February 23-25, 2011. CompanDX will also present three posters at the main Tri-Conference, describing novel "Time to Event" breast cancer and "Effect Based" TB tests and an innovative systems biology tool "Therapy Distiller."  In addition, Adam Gouldsworthy, Ph.D., Business Development Manager, CompanDX is presenting a talk, ""Distilling" Personalized Medicine – From Biomarker Discovery to "Time-to-Event Prognostics" at the Early Oncology Partnering Forum in San Francisco on February 21 at 3.26 p.m.

About CompanDX Ltd.

CompanDX is a biomarker discovery and service company that uses its "Distiller" platform to derive small composite biomarker panels from clients genomic and proteomic data in support of stratified clinical trials.  Privately-held, CompanDX is based in Nottingham, UK. Investors in the company include Lachesis and Mobius Funds. Additional information is available at www.compandx.com

About Clinical Reference Laboratory, Inc.

Established in 1979, CRL is a privately held reference laboratory in Lenexa, Kansas offering leading-edge testing services in the areas of Clinical Trials, Corporate Wellness Programs, Genomics, Insurance, Molecular Diagnostics, BioAnalytics and Toxicology. CRL is one of the largest single-site laboratories in the US and analyzes over 100 million tests annually.  In addition, CRL has a satellite laboratory near Cambridge, UK.  Additional information is available at www.crlcorp.com.


'/>"/>
SOURCE Clinical Reference Laboratory, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
4. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
5. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
6. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
7. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
8. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
9. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
10. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
11. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... DUBLIN , June 24, 2016 ... and Markets has announced the addition of the ... their offering. ... products and provides an updated review, including its applications ... covering the total market, which includes three main industries: ...
(Date:6/24/2016)... -- The Academy of Managed Care Pharmacy (AMCP) today ... allow biopharmaceutical companies to more easily share health care ... coverage decisions, a move that addresses the growing need ... The recommendations address restrictions in the sharing of product ... a prohibition that hinders decision makers from accessing HCEI ...
(Date:6/24/2016)... Calif. , June 24, 2016  American Respiratory Labs (ARL), ... is now able to perform sophisticated lung assessments in patients, homes, ... , Inc. Patients are no longer limited to ... EasyOne PRO ® , ARL patients like Jeanne R. of ... in the comfort of her own home. ...
Breaking Medicine Technology:
(Date:6/25/2016)... , ... June 25, 2016 , ... The temporary closing of Bruton Memorial Library on ... Observer , brings up a new, often overlooked aspect of head lice: the parasite’s ability ... fumigation is not a common occurrence, but a necessary one in the event that lice ...
(Date:6/25/2016)... City, Oklahoma (PRWEB) , ... June 25, 2016 ... ... helping both athletes and non-athletes recover from injury. Recently, he has implemented orthobiologic ... the Oklahoma City area —Johnson is one of the first doctors to perform ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced traumatic ... many turn to unhealthy avenues, such as drug or alcohol abuse, as a coping ... released tools for healthy coping following a traumatic event. , Trauma sufferers tend to ...
(Date:6/24/2016)... ... 2016 , ... Global law firm Greenberg Traurig, P.A. announced that 20 Florida ... their peers for this recognition are considered among the top 2 percent of lawyers ... as members of this year’s Legal Elite Hall of Fame: Miami Shareholders Mark ...
(Date:6/24/2016)... ... June 24, 2016 , ... People across the U.S. are ... Code Talker Award, an essay contest in which patients and their families pay tribute ... presented at the 2016 National Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) ...
Breaking Medicine News(10 mins):